*NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF NEW JERSEY

______________________________

:

CANDY KURY, on behalf of herself and all : 

others similarly situated, : Civil Action No. 11-803 (FLW)

: 

Plaintiff, : 

: OPINION

vs. : 

: 

:

ABBOTT LABORATORIES, INC. d/b/a :

ABBOTT SALES, MARKETING and :

DISTRIBUTION CO., et al., :

:

Defendants. :

______________________________: 

WOLFSON, United States District Judge:

Numerous class action suits have been filed around the country against defendants,

Abbott Laboratories, Inc. d/b/a Abbott Sales, Marketing and Distribution Co. and Abbott

Laboratories d/b/a Abbott nutrition (collectively, “Defendants”), relating to Defendants’

September 2010 recall of certain Similac-brand infant formula products. The recall was

precipitated by Defendants’ discovery of common warehouse beetles or beetle larvae in

certain Similac powder formulas. In this case, Plaintiff Candy Kury (“Plaintiff”), a New

Jersey resident, asserts claims involving fraud, product liability and unjust enrichment

against Defendants based upon allegations that these infant formulas caused substantial

harm. In addition, Plaintiff seeks to represent a class comprised of all New Jersey citizens

who purchased Similac products during an unspecified class period. In response to these

allegations, Defendants, in the instant matter, move to dismiss the Complaint in its entirety

1

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 1 of 14 PageID: 684
for failure to state a claim. For the reasons set forth herein, Plaintiffs’ Complaint is

dismissed; in particular, Plaintiff’s claimspursuant to the New Jersey Consumer Fraud Act,

breach of implied warranty, fraudulent concealment and unjust enrichment are dismissed

with prejudice. Plaintiff’s claim pursuant to the New Jersey Products Liability Act and

breach of express warranty are dismissed without prejudice. In that regard, Plaintiff has

leave to amend the Complaint with respect to those claims dismissed without prejudice

within fifteen days from the date of the Order accompanying this Opinion. 

BACKGROUND

On a motion to dismiss, the Court reviews the Complaint by taking its allegations as

true. Defendants manufacture, market, advertise, sell and distribute Similac brand infant

formula products , a leading brand “sold in grocery stores and pharmacies throughout the 1

United States, including in New Jersey.” Compl., ¶¶ 25, 26. According to Plaintiff,

Defendants specifically and extensively market Similac products to parents as a product

that “moms cancount on for trusted nutrition andthe formula that’s right for their babies.” 

Id. at ¶ 27. In that connection, the packaging of Similac products promotes uses such as

building “immune support,” “strong bones,” and “brain and eyes.” Id. at ¶ 28. In addition,

Defendants’ marketing materials claim that “[e]ach of the formulas in [the Similac] line

provides the balance of protein, minerals, and other nutrients that helps give babies a

strong start in life. A baby’s first year is so important, so count on Similac for nutrition you

can trust.” Id. 

In and around September 2010, during an internal quality review, Defendants

According to Defendants, the Similac line consists of at least ten different 1

products, each available in a variety of sizes. 

2

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 2 of 14 PageID: 685
discoveredthat piecesof commonwarehousebeetles or beetle larvae were present in certain

finished Similac products, which were manufactured in a single facility. Id. at ¶¶ 30-31.

Thereafter, Defendants announced a voluntary recall of those products. In that particular

announcement, Defendants advised the public that “the United States Food and Drug

Administration (“FDA”) has determined that while the formula containing these beetles

poses no immediate health risk, there is a possibility that infants who consume formula

containing the beetles or their larvae could experience symptoms of gastrointestinal

discomfort and refusal to eat as a result of small insect parts irritating the GI tract.” 

Compl., ¶ 31. Defendants’ recall encompassed all Similac powdered formula sold in

rectangular tubs, including certain Similac powder product lines offered in plastic

containers, and certain Similac powder product lines offered in sizes such as 8-ounce, 12.4-

ounce and 12.9-ounce cans. Id. at ¶ 34. 

Plaintiff alleges that at an unspecified point in time, she purchased one or more

unspecified Similac-brand products. Id. at ¶¶ 7, 39-40. Plaintiff further alleges that in

purchasing the products, she “relied upon the misrepresentations made by Defendants

about the quality and safety of Similac products, and that Similac products would not

adversely affect her infant child’s health.” Id. at ¶ 39. Moreover, Plaintiff complains that

Defendants “should have known that the failure to exercise proper safety standards and

equipment management would have led to insects infiltrating Similac products, thereby

creating formulas unsafe for infant consumption.” Id. at ¶ 45. 

Based upon these allegations, Plaintiff, in herComplaint,asserts five causesof action

arising out of statutory violations and common law: (1) New Jersey’s Consumer Fraud Act

(“NJCFA”); (2) New Jersey Products Liability Act (“NJPLA”); (3) Breach of Express and

3

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 3 of 14 PageID: 686
Implied Warranty; (4) Fraudulent Concealment; and (5) Unjust Enrichment. Because of

these violations, Plaintiff claims that she sufferedinjury in fact, a loss of money or property,

the personal expenditure of time and resources and/or other forms of injury, damage,

mental anguish, and/or physical pain and suffering. See Compl., ¶¶ 54, 64, 71. 

DISCUSSION

I. Standard of Review

When reviewing a motion to dismiss on the pleadings, courts "accept all factual

allegations as true, construe the complaint in the light most favorable to the plaintiff, and

determine whether, under any reasonable reading of the complaint, the plaintiff may be

entitled to relief." Phillips v. County of Allegheny, 515 F.3d 224, 233 (3d Cir. 2008) (citation

and quotations omitted). In Bell Atlantic Corporation v. Twombly, 550 U.S. 544, 127 S. Ct.

1955, 167 L. Ed. 2d 929 (2007), the Supreme Court clarified the 12(b)(6) standard.

Specifically, the Court "retired" the language contained in Conley v. Gibson, 355 U.S. 41,

45-46(1957), that "a complaint should not be dismissed for failure to state a claim unless

it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim

which would entitle him to relief." Twombly, 550 U.S. at 561 (quoting Conley, 355 U.S. at

45-46). Instead, the factual allegations set forth in a complaint "must be enough to raise a

right to relief above the speculative level." Twombly, 550 U.S. at 555. As the Third Circuit

has stated, "[t]he Supreme Court's Twombly formulation of the pleading standard can be

summed up thus: 'stating ... a claim requires a complaint with enough factual matter (taken

as true) to suggest' the required element. This 'does not impose a probability requirement

at the pleading stage,' but instead 'simply calls for enough facts to raise a reasonable

expectation that discovery will reveal evidence of'the necessary element." Phillips, 515 F.3d

4

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 4 of 14 PageID: 687
at 234 (quoting Twombly, 550 U.S. at 555).

In affirming that Twombly standards apply to all motions to dismiss, the Supreme

Court has further explained the principles. First, "the tenet that a court must accept as true

all of the allegations contained in a complaint is inapplicable to legal conclusions." Ashcroft

v. Iqbal, 556 U.S. 662, 129 S.Ct. 1937, 1948-49, 173 L. Ed. 2d 868 (2009). Second, "only a

complaint that states a plausible claim for relief survives a motion to dismiss." Id.

Therefore, "a court considering a motion to dismiss can choose to begin by identifying

pleadings that, because they are no more than conclusions, are not entitled to the

assumption of truth." Id. at 1949. Ultimately, "a complaint must do more than allege the

plaintiff's entitlement to relief. A complaint has to 'show' such an entitlement with its facts."

Fowler v. UPMC Shadyside, 578 F.3d 203, 211 (3d Cir. 2009). Moreover, in deciding a

motion to dismiss, the court may consider the allegations in the complaint, exhibits

attached to the complaint, matters of public record, and documents that form the basis of

plaintiff's claim. Lum v. Bank of Am., 361 F.3d 217, 222 n. 3 (3d Cir. 2004).

The Third Circuit recently reiterated that "judging the sufficiency of a pleading is a

context-dependent exercise" and "[s]ome claims require more factual explication than

others to state a plausible claim for relief." West Penn Allegheny Health System, Inc. v.

UPMC, 627 F.3d 85, 2010 WL 4840093, at *8 (3d Cir. 2010). This means that, "[f]or

example, it generally takes fewer factual allegations to state a claim for simple battery than

to state a claim for antitrust conspiracy." Id. That said, the Rule 8 pleading standard is to

be applied "with the same level of rigor in all civil actions." 627 F.3d 85, Id. at *7 (quoting

Ashcroft, 129 S.Ct. at 1953).

5

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 5 of 14 PageID: 688
II. PLA: Subsumption 

At the outset, before the Court reviews the sufficiency of the allegations, it first

resolves a legal question: whether Plaintiff’s assertion of her NJFLA claim effectively

subsumes Plaintiff’sother claimsunder the NJCFA, breach of impliedwarranty, fraudulent

concealment and unjust enrichment. The Court answers in the affirmative. 

The New Jersey Products Liability Act, N.J.S.A. 2A:58C-1, et seq., was enacted “to

limit the expansion of products-liability law” and “to limit the liability of manufacturers so

as to balance[] the interests of the public and the individual with a view towards economic

reality.” Zaza v. Marquess & Nell, Inc., 144 N.J. 34, 47 (1996)(quotations and citations

omitted). The NJPLA, therefore, "established the sole method to prosecute a product

liability action[,]" and after its enactment, "only a single product liability action remains." 

Tirrell v. Navistar Int'l, Inc., 248 N.J. Super. 390, 398-99 (App. Div.), certif. denied, 126

N.J. 390 (1991). In that regard, the Third Circuit has long ago proclaimed that the NJPLA

"effectively creates an exclusive statutory cause of action for claims falling within its

purview." Repola v. Morbark Indus., Inc., 934 F.2d 483, 492 (3d Cir. 1991). Indeed, “the

NJPLA generally subsumes common law product liability claims, thus establishing itself as

the sole basis of relief under New Jersey law available to consumers injured by a defective

product." Id.; see In re Lead Paint Litig., 191 N.J. 405, 436 (2007)(the NJPLA accomplishes

its liability-limiting function by creating “one unified, statutorily defined theory of recovery

for harm caused by a product.”). 

Generally, the NJPLA “encompass[es] virtually all possible causes of action relating

to harms caused by consumer and other products,” In re Lead Paint, 191 N.J. at 436-37,

“except . . . breach of an express warranty.” N.J.S.A. 2A:58C-1b(3). Because of the breadth

6

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 6 of 14 PageID: 689
of the NJPLA, there is no question that New Jersey federal and state courts have

consistently dismissed product liability claims based on common-law theories when the

heart of those theories is the potential "harm caused by a product." See, e.g., Port Auth. of

N.Y. & N.J. v. Arcadian Corp., 189 F.3d 305, 313 (3d Cir. 1999) (dismissing negligence

claim, stating that "under New Jersey law negligence is no longer viable as a separate claim

for harm caused by a product"); Thomas v. Ford Motor Co., 70 F. Supp. 2d 521, 528-29

(D.N.J. 1999) (dismissing common-law claim for negligent manufacture); Reiff v.

Convergent Techs., 957 F. Supp. 573, 583 (D.N.J. 1997)(dismissing negligence and breach

of warranty claims); McWilliams v. Yamaha Motor Corp. USA, 780 F. Supp. 251, 262

(D.N.J. 1991) (dismissing claims of negligence and breach of implied warranty), aff'd in

part, rev'd in part on other grounds, 987 F.2d 200 (3d Cir. 1993); Green v. Gen. Motors

Corp., 310 N.J. Super. 507, 517 (App. Div. 1998) (stating that "causes of action for

negligence, strict liability and implied warranty have been consolidated into a single

product liability cause of action" under the NJPLA). 

Moreover, courts have also found that the NJPLA subsumes common law and

statutory fraud claims so long as the harm alleged was caused by a product. See Brown v.

Philip Morris, Inc., 228 F. Supp. 2d 506, 517 (D.N.J. 2002)(fraud claim preempted by the

NJPLA when defendant’s alleged misrepresentations resulted in “harm caused by a

product”); Sinclair, 195 N.J. at 66 (statutory consumer fraudclaim subsumed by the NJPLA

when the “[t]he heart of plaintiff’s case [was] the potential harm caused by Merk’s drug”);

McDarby v. Merck & Co., 401 N.J. Super. 10, 95-96 (App. Div. 2008)(statutory consumer

fraud claim subsumed by the NJPLA because “the gravamen of [the] claim was that Merk

marketed Vioxx fully aware of its cardiovascular risk [and] made misrepresentations[] and

7

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 7 of 14 PageID: 690
. . . omis[ssions]” in connection with its marketing). Indeed, this Court has previously, in

Lopienski v. Centocor, Inc., No. 07-4519, 2008 WL 2565065, at *1 n.2 (D.N.J. Jun. 25,

2008), found that claims of negligence, breach of implied warranty, negligent and

fraudulent misrepresentation, statutory consumer fraud and fraudulent concealment are

subsumed by the NJPLA when the theory of a case is premised upon product liability. 

Here, there is no doubt that Plaintiff’s case is based on a product liability theory. In

fact, in the first paragraph of the Complaint, Plaintiff characterizes this case as involving

Defendants’ manufacturing and selling of various defective Similac brand infant powder

formulas. Compl., ¶ 1. Simply, the heart of Plaintiff’s complaints is that her or her child’s

injuries – economic and non-economic alike – resulted from ingesting the allegedly

defective Similac products that Defendants marketed and sold. Plaintiff, however, aruges

that the causes of action, not involving the NJPLA or express warranty, are not subsumed

by the NJPLA because in addition to “the type of damages [recoverable] under the

[NJPLA],” such as personal injuries and emotional distress, “she is also seeking damages

for the loss of the product itself,” which are “specifically excluded[from recovery under] the

[NJPLA].” Plaintiff’s Opp. at p.11. Significantly, Plaintiff implicitly acknowledges that each

of her claims, which are not brought pursuant to the NJPLA or the breach of express

warranty, are barred by the NJPLA, except to the extent those claims seek the lost value of

the product itself. 

Nevertheless, even the claim of lost value in this case is not sufficiently

distinguishable from the broad harm encompassed by the NJPLA. As the court has

explained in Felluer v. Tri-Union Seafoods, LLC, No. 06-0688, 2010 U.S. Dist. LEXIS

36195, at *15 (D.N.J. Apr. 13, 2010), “[t]he fact that [a plaintiff] . . . seeks economic

8

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 8 of 14 PageID: 691
damages to reimburse her for the cost of the product (in addition to personal injury

damages) does not change the fact that this is, in essence, a product liabilities claim.” The

court, deriving its reasoning from the New Jersey appellate division decision in McDarby,

went on to hold that because the NJPLA’s definition of harm covers virtually any economic

harm caused by the allegedly defective product, a plaintiff should not be permitted to bring

separate claims under the NJPLA and NJCFA “as the [NJPLA] was intended to unify

product liabilities causes of action into a single claim.” Id. at *15-16 (citing McDarby, 401

N.J. Super at 277-78). Moreover, a plaintiff should not be able to benefit from provisions

– providing treble damages and attorney’s fees – contained in the NJCFA despite the fact

that such provisions were intentionally excluded from the NJPLA. See McDarby, 401 N.J.

Super at 278. Indeed, this line of reasoning has been adopted by courts in this district. See

Arlandson v. Hartz Mountain Corp., No. 10-1050, 2011 WL 2112494, at *11 (D.N.J. May 25,

2011)(dismissing claim for unjust enrichment where the complaint’s “core issue” was the

harmfulness of the defendant’sproduct); O’Donnell v. Kraft Foods, Inc., No. 09-4448, 2010

WL 1050139, at *3 (D.N.J. Mar. 18, 2010)(plaintiffs’ claim of lost value from purchasing the

hot dogs was preempted by NJPLA, because those products’ lost value resulted from “the

increased risk of cancer [plaintiffs] allege[d] arises from consumption of [the] product . .

.”); Levinson v. Johnson & Johnson Consumer Cos., 2010 U.S. Dist. LEXIS 8654 (D.N.J.

Feb. 1, 2010); Smith v. Merial Ltd., No. 10-439, 2011 U.S. Dist. LEXIS 56461, at *11-13

(D.N.J. May 26, 2011) (“Plaintiffs attempt to classify their claims as non-product liability

claims by alleging only economic damages related to the price of the product as opposed to

damages related to the harm caused by the product. However, limiting a claim to economic

injury and the remedy sought to economic loss cannot be used to obviate the PLA.”

9

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 9 of 14 PageID: 692
(citations and quotations omitted)). 

Accordingly,basedon the allegations here, any economic loss or non-economic loss -

including the cost of purchasing the Similac products - Plaintiff allegedly suffered, resulted

from her infant ingesting the powder formulas, which arises solely under product liability. 

See Smith, 2011 U.S. Dist. LEXIS 56461 at *13 (“Though Plaintiffs assert contract,

quasi-contract, and consumer fraud claims, the core issue underlying Plaintiffs' claims is

that the chemicals in Frontline products are dangerous and caused physical damage to

Plaintiffs' property, in the form of harm to their pets' health.”). This type of harm falls

squarely within the exclusive purview of the NJPLA and as such, Plaintiff’s claimspursuant

to the NJCFA, breach of implied warranty, fraudulent concealment and unjust enrichment

are subsumed by the NJPLA. Plaintiff’s proper recourse is through the NJPLA and/or 2

breach of express warranty, as explained below.

Plaintiff relies on Shannon v. Howmedica Osteonics Corp., No. 09-4171, 2010 2

U.S. Dist. LEXIS 8621, at *7 (D.N.J. Feb. 1, 2010), for the proposition that her claims

based upon the lost value of the Similac products are separate and distinct from her

NJPLA claim. The Court does not find the analysis of that case persuasive as the

Shannon court provided little reasoning for its holding. Plaintiff does not advance any

other authorities to support her position. Nonetheless, even if lost value is an exception

to NJPLA’s purview, Plaintiff’s claims relating to the loss value of the products may also

be dismissed on the ground that Plaintiff was offered a refund for the recalled products.

Indeed, Defendants announced in a public notice that they would provide a refund to

any purchaser of Similac products that were the subject of the recall. While Plaintiff

does not allege in the Complaint that she has received a refund, the mere tender of relief

moots her claim for the purchase price of the Similac products. See Gates v. City of

Chicago, 623 F.3d 389, 413 (7 Cir. 2010); see, e.g., Brown v. Abbott Labs., Inc., No. 10- th

6674, 2011 U.S. Dist. LEXIS 110175, at *15-16 (N.D. Ill. Sep. 27, 2011); Jovine v. Abbott

Labs., Inc., 795 F. Supp. 2d 1331 (S.D. Fla. 2011); Tosh-Surryhne v. Abbott Labs. Inc.,

No. 10-2603, 2011 U.S. Dist. LEXIS 110107, at *10-11 (E.D. Cal. Sept. 26, 2011); Jasper v.

Abbott Labs., Inc., No. 11-229, 2011 U.S. Dist. LEXIS 73806, at *18-19 (N.D. Ill. Jul. 8,

2011); Bland v. Abbott Labs., No. 11-430, 2012 U.S. Dist. LEXIS 1732, at *6 (W.D. Ky.

Jan. 6, 2012). 

10

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 10 of 14 PageID: 693
III. New Jersey’s Products Liability Act

To properly plead a cause of action under the NJPLA, a plaintiff must allege that the

defendant manufactured the product, that a reasonably foreseeable user was injured, that

the product was defective, that the defect existed when it left the defendant's control, and

that the defect was the factual and proximate cause of the plaintiff's injury. Myrlak v. Port

Auth. of N.Y. and N.J., 157 N.J. 84, 97 (1999); Coffman v. Keene Corp., 133 N.J. 581, 593

(1993); Michalko v. Cooke Color & Chem. Corp., 91 N.J. 386, 394 (1982). Importantly, the

New Jersey Supreme Court has advised that the NJPLA requires a physical injury. Sinclair,

195 N.J. at 64 (under the NJPLA, “the word ‘injury’ is surrounded by ‘physical illness,’

which explicitly requires something physical, and ‘death,’ which inherently is physical.”).

In this case, Defendants challenge the sufficiency of Plaintiff’s NJPLA claim based

on Plaintiff’s failure to plead any physical injury. The Court agrees; nothing in the

allegations contained in the Complaint sets forth any physical injuries to Plaintiff or

Plaintiff’s infant child, who is not a party in this case. Other than conclusory and vague 3

allegations that Plaintiff suffered damages, mental anguish and pain and suffering, the

extent of any physical damages suffered by Plaintiff or Plaintiff’s infant child are contained

Having reviewed Plaintiff’s Complaint, the Court finds that there are no 3

allegations that the Similac products Plaintiff purchased were subject to the September

2010 recall. As Plaintiff avers in her Complaint that only certain types of Similac

products were recalled, Plaintiff fails to identify that the products she purchased were

subject to the recall. Rather, Plaintiff merely alleges that “Defendants misled Plaintiff

into purchasing the unsafe Similac products,” see Compl., ¶ 39, and that “Plaintiff and

the members of the putative Classes would not have purchased the recalled Similac

products had they known of their defective condition.” These bare allegations are

insufficient under the Iqbal standard. Indeed, Plaintiff recognizes this deficiency and

requests that “if given the opportunity to amend the Complaint, Plaintiff would be able

to show that she purchased products that should have been recalled . . . .” Plaintiff’s

Opp., pp. 8-9. 

11

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 11 of 14 PageID: 694
in these allegations: “Defendants discovered that Similac-brand formulas had been

contaminated and contained beetles and beetle larvae, which if consumed by infant

children, could lead to serious health concerns, including gastrointestinal problems,

diarrhea and the like.” Compl., ¶ 1 (emphasis added). In that connection, Plaintiff alleges

that “Defendants caused serious injury to Plaintiff and the putative Classes she seeks to

represent.” Id. at ¶ 3. These are clearly insufficient under the Iqbal standard to allege a

physical injury, and as a result, Plaintiff’s NJPLA claim is dismissed.4

IV. Breach of Express Warranty 

An express warranty claim is codified under N.J.S.A. 12A:2-313, which provides:

(1) Express warranties by the seller are created as follows: 

(a) Any affirmation of fact or promise made by the seller to the buyer which

relates to the goods and becomes part of the basis of the bargain creates an

express warranty that the goods shall conform to the affirmation or promise.

(b)Any description of the goods which is made part of the basis of the bargain

creates an express warranty that the goods shall conform to the description.

(c) Any sample or model which is made part of the basis of the bargain creates

an express warranty that the whole of the goods shall conform to the sample

or model.

(2) It is not necessary to the creation of an express warranty that the seller use 

formal words such as "warrant" or "guarantee" or that he have a specific intention

to make a warranty, but an affirmation merely of the value of the goods or a

statement purporting to be merely the seller's opinion or commendation of thegoods

does not create a warranty.

N.J.S.A. 12A:2-313; Gupta v. AshaEnters., L.L.C., 422 N.J. Super. 136, 153 (App. Div. 2011).

As a final note, Defendants ask the Court dismiss the Complaint in its entirety 4

because Plaintiff’s allegations of injury do not suggest that Plaintiff suffered any injury. 

However, because the Court has already dismissed Plaintiff’s claims on various grounds

set forth above, it need not consider this question in connection with the other causes of

action.

12

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 12 of 14 PageID: 695
Here, Defendants argue that the Court should dismiss this claim for three reasons:

(1) Plaintiff fails to allege that there was anything wrong with any unit of Similac she

purchased; (2) all of Defendants’ statements that Plaintiff pleads are actionable are either

not actually alleged to be false or mere puffery; and (3) Plaintiff fails to plead that she

provided the requisite pre-litigation notice of breach. Dispositive of the claim for breach

of express warranty is Plaintiff’s failure to provide a pre-litigation notice to Defendants

regarding the alleged breach. 

New Jersey has adopted the Uniform Commercial Code's ("UCC") notice

requirement for an express warranty claim. Luppino v. Mercedes-Benz USA, LLC, No. 09-

5582, 2011 U.S. Dist. LEXIS 65495, at *7 (D.N.J. Jun. 20, 2011); Joc, Inc. v. Exxonmobil

Oil Corp., No. 08-5344, 2010 WL 1380750, at *4 (D.N.J. Apr. 1, 2010); Slack v. Suburban

Propane Partners, L.P., No. 10-2548, 2010 WL 5392845, at *4-5 (D.N.J. Dec. 22, 2010). 

It provides: "Where a tender has been accepted . . . the buyer must within a reasonable time

after [s]he discovers or should have discovered any breach notify the seller of breach or be

barred from any remedy." N.J.S.A. 12A:2-607(3)(a). Based upon the language, this

statutory notice is a “condition precedent to filing any suit for breach of warranty.” Joc,

2010 WL 1380750 at *4. 

There is no dispute that Plaintiff has failed to plead that she provided the prelitigation notice of breach. Indeed, Plaintiff has not disputed this fact in her opposition. 

More importantly, Plaintiff offers no excuse or explanation for her failure to do so. 

Accordingly, because Plaintiff has failed to allege that the condition precedent has been met

– sending a pre-litigation notice – Plaintiff’s express warranty claim necessarily fails. See

Luppino, 2011 U.S. Dist. LEXIS 65495 at *7 (“At no time has any court in this district or in

13

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 13 of 14 PageID: 696
the state of New Jersey found that a buyer is not required to provide a direct seller with

pre-suit notice in an action for express breach of warranty. Thus, Stern and Casiero's

admission that they have failed to provide notice to Defendant proves fatal to their breach

of express warranty claims.”). However, since the Court cannot determinewhetherPlaintiff

in fact sent a notice to Defendants, or whether Plaintiff is excused from sending a notice,

this claim is dismissed without prejudice. 

CONCLUSION

For the foregoing reasons, the Court grants Defendants’ motion to dismiss. In sum,

Plaintiff’s claims pursuant to the NJCFA, breach of implied warranty, fraudulent

concealment and unjust enrichment are dismissed as they are subsumed by NJPLA. 

Plaintiff’s claim pursuant to the NJPLA and breach of express warranty are dismissed

without prejudice. In that regard, Plaintiff has leave to amend the Complaint with respect

to those claims dismissed without prejudice within fifteen days from the date of the Order

accompanying this Opinion. 

/s/ Freda L. Wolfson 

The Honorable Freda L. Wolfson

United States District Judge

Date: January 17, 2012

14

Case 3:11-cv-00803-FLW -TJB Document 36 Filed 01/17/12 Page 14 of 14 PageID: 697